Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. For over three decades, we’ve been working to achieve mass mental health throughout the United States, Canada, and Europe.

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JUNE 10, 2021

In short the study learns that legalized states tend not to have their roads overcrowded with stoned drivers and cannabis users like alcohol users self police their behaviour. However, relatively few studies have used self-reported data for this purpose [ 11 , 12 , 13 ]. Under this restriction, we analyzed data from 11,816 respondents.

Policy 59

Policy Safety Marijuana Data 59

Cannabis Law Report

NOVEMBER 24, 2021

Medical publications, are, in the main fairly positive toward cannabis. Published by The Journal of Cannabis Research. Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. At the same time, the outlook on cannabis research data is largely positive.

Research and Development 52

Research and Development Medicine Access Media 52

Green Relief

MAY 13, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. government still maintains that cannabis is a dangerous drug with no medical value. How does cannabis, and THC , in particular, confer neuroprotective effects? But the U.S.

THC 64

THC CBD Cannabinoids Research and Development 64

Green Relief

MAY 12, 2018

The benefits of CBD-rich cannabis concentrates for chronic traumatic encephalopathy (CTE) are well-known among football players and other pro athletes. government still maintains that cannabis is a dangerous drug with no medical value. How does cannabis, and THC , in particular, confer neuroprotective effects? But the U.S.

Research and Development 40

Research and Development Cannabinoids Therapy CBD 40

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73